{
    "clinical_study": {
        "@rank": "153218", 
        "arm_group": {
            "arm_group_label": "Neoadjuvant Chemotherapy + Chemoradiation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Bladder preservation in patients with complete response after neoadjuvant chemotherapy will\n      lead to equivalent or superior relapse free rates compared to cystectomy rates from\n      historical controls."
        }, 
        "brief_title": "Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy", 
        "condition": [
            "Bladder Cancer", 
            "Bladder Carcinoma", 
            "Transition Cell Cancer", 
            "Muscle Invasive Bladder Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Carcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically proven diagnosis of primary carcinoma of the bladder(transitional cell\n             cancer). Must be operable patients with muscularis propria invasion and AJCC clinical\n             stages T2-4a, N0 or N+, M0.  Patients with prostatic urethra involvement with\n             transitional cell cancer (TCC) are eligible if it is completely resected and the\n             patient has no evidence of stromal invasion of the prostate.\n\n          -  Patients must be able to tolerate systemic chemotherapy combined with pelvic\n             radiation therapy and radical cystectomy\n\n          -  Zubrod Performance Status of \u22641.\n\n          -  Age \u226518.\n\n          -  CBC/differential obtained no more than 8 weeks prior to enrollment on study, with\n             adequate bone marrow function defined as follows:\n\n               -  WBC \u2265 4000/ml\n\n               -  Absolute neutrophil count (ANC) \u22651,800 cells/mm\n\n               -  Platelets \u2265100,000 cells/mm\n\n               -  Hemoglobin \u2265 10.0 mg/dl (Note: the use of transfusion or other intervention to\n                  achieve this level is acceptable)\n\n          -  Serum bilirubin of 2.0mg or less;\n\n          -  Serum creatinine of 1.5mg or less;  creatinine clearance of 60ml/min or greater no\n             more than 8 weeks prior to enrollment (Note: calculated creatinine clearance is\n             permissible, using Cockcroft-Gault formula.  If the creatinine clearance is greater\n             than 60ml/min, then a serum creatinine of up to 1.8mg is allowable at the discretion\n             of the principal investigator.)\n\n          -  Patients must be willing and able to provide study-specific informed consent prior to\n             study entry\n\n        Exclusion Criteria:\n\n          -  Tumor related untreated active hydronephrosis\n\n          -  Evidence of distant metastases.\n\n          -  Diffuse bladder carcinoma in situ (CIS) not able to be encompassed in a boost\n             radiotherapy volume.\n\n          -  Previous systemic chemotherapy (for any cancer) or pelvic radiation therapy\n\n          -  A prior or concurrent malignancy of any other site or histology unless the patient\n             has been disease free for greater than or equal to five years except for non-melanoma\n             skin cancer and/or stage T1a prostate cancer or carcinoma in situ of the uterine\n             cervix\n\n          -  Patients that are not candidates for radical cystectomy (T4b disease are considered\n             unresectable)\n\n          -  Pregnancy or women of childbearing potential [not post-menopausal or permanently\n             sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy)] and men who\n             are sexually active and not willing/able to use medically acceptable forms of\n             contraception; this exclusion is necessary because the treatment involved in this\n             study may be significantly teratogenic\n\n          -  Severe active co-morbidity:\n\n               -  Unstable angina and/or congestive heart failure requiring hospitalization within\n                  the last 6 months\n\n               -  Transmural myocardial infarction within the last 6 months\n\n               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the\n                  time of registration\n\n               -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness\n                  requiring hospitalization or precluding study therapy at the time of enrollment\n\n               -  History of hepatic insufficiency resulting in clinical jaundice and/or\n                  coagulation defects (Note: laboratory tests for liver function and coagulation\n                  parameters are not required for enrollment into this protocol)\n\n               -  Known diagnosis of Acquired Immune Deficiency Syndrome (AIDS) based upon current\n                  CDC definition (Note: HIV testing is not required for enrollment into this\n                  protocol).  The need to exclude patients with AIDS from this protocol is\n                  necessary because the treatments involved in this protocol may be significantly\n                  immunosuppressive.\n\n               -  As determined by the investigator or principal investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145390", 
            "org_study_id": "UMIAMI-20130896"
        }, 
        "intervention": [
            {
                "arm_group_label": "Neoadjuvant Chemotherapy + Chemoradiation", 
                "description": "The following will be performed by the participating urologist:\ncystoscopic evaluation\nbimanual examination under anesthesia,\nas thorough as possible a transurethral resection (TUR) of the bladder tumor,\nand a biopsy of the prostatic urethra including both mucosa and stroma using a resection loop.", 
                "intervention_name": "Transurethral Resection of the Bladder Tumor & Cystoscopy", 
                "intervention_type": "Procedure", 
                "other_name": "TURBT"
            }, 
            {
                "arm_group_label": "Neoadjuvant Chemotherapy + Chemoradiation", 
                "description": "All patients will receive the neoadjuvant course of chemotherapy.  This regimen will begin within 8 weeks following the TURBT and cystoscopic evaluation by the urologic surgeon.  Ideally, treatment should start within 8 weeks and on a Monday.\nNeoadjuvant chemotherapy: Cisplatin (70 mg/m2) will be administered as a sixty-minute infusion (+/- 10 minutes) on day 1 (outpatient regimen) or day 2 (inpatient regimen) of each 21-day cycle, for four cycles. Cisplatin therapy will begin within 8 weeks following the TURBT & Cystocopy\nConcurrent Chemotherapy w/Radiation: Cisplatin (35 mg/m2) will be administered as a 60 minute infusion (+/- 10 minutes) starting on day 1 of radiation, and on days 8,15,22,29.", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "Platinol"
            }, 
            {
                "arm_group_label": "Neoadjuvant Chemotherapy + Chemoradiation", 
                "description": "All patients will receive the neoadjuvant course of chemotherapy.  This regimen will begin within 8 weeks following the TURBT and cystoscopic evaluation by the urologic surgeon.  Ideally, treatment should start within 8 weeks and on a Monday.\nNeoadjuvant chemotherapy: Gemcitabine (1000 mg/m2) will be administered intravenously over 30-60 minutes (preferably 30 minutes) on Days 1 and 8 of each 21-day cycle, for four cycles.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Neoadjuvant Chemotherapy + Chemoradiation", 
                "description": "All patients will receive 25 daily fractions (5 weeks) of radiation therapy for  5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment.  Radiation therapy will be started within 6 weeks following the neoadjuvant chemotherapy.  The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes.  The pelvic lymph nodes will receive 45 Gy in 25 fractions at 1.8 Gy per fraction.  The whole bladder and prostate will receive 50 Gy in 25 fractions at 2.0 Gy per fraction.  The tumor boost area will be defined as the area of bladder involved by tumor based on TURBT, CT imaging, and lipiodol injection at time of cystoscopy, and will receive 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day.  Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume.", 
                "intervention_name": "Intensity Modulated Radiation Therapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "IMRT", 
                    "VMAT"
                ]
            }, 
            {
                "arm_group_label": "Neoadjuvant Chemotherapy + Chemoradiation", 
                "intervention_name": "Quality of Life Questionnaires", 
                "intervention_type": "Behavioral", 
                "other_name": [
                    "The Expanded Prostate Cancer Index Composite SF-12 Questionnaire", 
                    "EPIC/SF-12", 
                    "International Prostate Symptom Score", 
                    "IPSS"
                ]
            }, 
            {
                "arm_group_label": "Neoadjuvant Chemotherapy + Chemoradiation", 
                "description": "10-20mL clean-catch urine at the following timepoints: i.\tPre-treatment (Evaluation 1) ii.\tPost-neoadjuvant chemotherapy (Evaluation 2) iii.\tPost-consolidation chemoradiotherapy or cystectomy iv.\tAt one year follow-up v.\tAt the time of relapse", 
                "intervention_name": "Urine Collection for Molecular Analysis", 
                "intervention_type": "Genetic"
            }, 
            {
                "arm_group_label": "Neoadjuvant Chemotherapy + Chemoradiation", 
                "description": "Whole blood and plasma at the following timepoints.\na. Serum: 5-10mL of whole blood in 1 red-top tube and centrifuge i. Pre-treatment (Evaluation 1) ii. Post-neoadjuvant chemotherapy (Evaluation 2) iii. Post-consolidation chemoradiotherapy or cystectomy iv. At one year follow-up v. At the time of relapse\nb. Plasma: 5-10mL of anticoagulated whole blood in EDTA tube (purple/lavender top) and centrifuge i. Pre-treatment (Evaluation 1) ii. Post-neoadjuvant chemotherapy (Evaluation 2) iii. Post-consolidation chemoradiotherapy or cystectomy iv. At one year follow up v. At the time of relapse", 
                "intervention_name": "Blood Collection for Molecular Analysis", 
                "intervention_type": "Genetic"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bladder Cancer", 
            "Bladder Carcinoma", 
            "Transition Cell Cancer", 
            "TCC", 
            "Muscle Invasive Bladder Carcinoma"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "email": "a.ishkanian@med.miami.edu", 
                "last_name": "Adrian S Ishkanian, MD", 
                "phone": "786-243-5454"
            }, 
            "contact_backup": {
                "email": "sylvester@emergingmed.com", 
                "last_name": "University of Miami Sylvester Comprehensive Cancer Center", 
                "phone": "866-574-5124"
            }, 
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "University of Miami Sylvester Comprehensive Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Adrian S Ishkanian, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jaime Merchan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rakesh Singal, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alan Pollack, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Murugesan Manoharan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthew Abramowitz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Merce Jorda, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy", 
        "overall_official": {
            "affiliation": "University of Miami Sylvester Comprehensive Cancer Center", 
            "last_name": "Adrian S Ishkanian, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the rate of failure free survival with intact bladder (FFSIB) at two years in patients undergoing bladder preservation.", 
            "measure": "Percentage of patients experiencing failure free survival with intact bladder (FFSIB)", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145390"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The two year rate of failure free survival (FFS). This will include locoregional recurrence, and distant metastases.", 
                "measure": "Percentage of patients experiencing failure free survival at two years", 
                "safety_issue": "No", 
                "time_frame": "2 Years"
            }, 
            {
                "description": "The rate of acute and late grade 2 or higher (CTCAE v4.0) treatment related GU, GI and hematologic toxicity of bladder preservation.", 
                "measure": "Number of patients experiencing acute and late grad 2 or higher treatment related adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "Two years"
            }
        ], 
        "source": "University of Miami Sylvester Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Miami Sylvester Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}